LONDON and SHANGHAI, China, Nov. 21, 2023 (GLOBE NEWSWIRE) Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), and WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announce that they have entered into a license agreement under which Myricx will have exclusive
Myricx Bio Enters Into An Exclusive Antibody License Agreement With Wuxi Biologics menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.